GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Magenta Therapeutics Inc (NAS:MGTA) » Definitions » 14-Day RSI

Magenta Therapeutics (Magenta Therapeutics) 14-Day RSI : 36.90 (As of May. 11, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Magenta Therapeutics 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-11), Magenta Therapeutics's 14-Day RSI is 36.90.

The industry rank for Magenta Therapeutics's 14-Day RSI or its related term are showing as below:

MGTA's 14-Day RSI is not ranked
in the Biotechnology industry.
Industry Median: 47.39 vs MGTA: 36.90

Competitive Comparison of Magenta Therapeutics's 14-Day RSI

For the Biotechnology subindustry, Magenta Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Magenta Therapeutics's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Magenta Therapeutics's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Magenta Therapeutics's 14-Day RSI falls into.



Magenta Therapeutics  (NAS:MGTA) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Magenta Therapeutics  (NAS:MGTA) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Magenta Therapeutics 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Magenta Therapeutics's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Magenta Therapeutics (Magenta Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
100 Technology Square, 5th Floor, Cambridge, MA, USA, 02139
Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, MGTA-45 and others.
Executives
Peter Evan Harwin director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Tomas Kiselak director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Funds Management Llc director, 10 percent owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Edward Carr officer: CHIEF ACCOUNTING OFFICER 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Ryan Savitz officer: CHIEF FINANCIAL OFFICER 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Lei Meng director 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Simrat Randhawa officer: Chief Medical Officer 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Avidity Partners Management Lp director 2828 N HARWOOD STREET, SUITE 1220, DALLAS TX 75201
Marino Garcia director, officer: CEO and President C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVENUE, SUITE 2012, NEW YORK NY 10170
Adam M Veness officer: See Remarks C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Moulder Leon O Jr director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Paula Soteropoulos director 49 WINONA STREET, PEABODY MA 01960
Jonathan Violin director 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Third Rock Ventures Iv, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Michael Vasconcelles director C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140

Magenta Therapeutics (Magenta Therapeutics) Headlines

From GuruFocus

Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan

By sperokesalga sperokesalga 03-31-2023